Trevi Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Trevi Therapeutics has a total shareholder equity of $59.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $68.9M and $9.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$65.49m |
Equity | US$58.97m |
Total liabilities | US$9.94m |
Total assets | US$68.91m |
Recent financial health updates
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Sep 27We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
May 24Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
Jan 27Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Mar 23Recent updates
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Sep 27We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
May 24Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
Jan 27Trevi adds 19% on full data set from mid-stage cough study
Sep 19Trevi Therapeutics: Moving Forward
Sep 11Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Mar 23Trevi has a new development chief
Feb 01Financial Position Analysis
Short Term Liabilities: TRVI's short term assets ($67.3M) exceed its short term liabilities ($9.1M).
Long Term Liabilities: TRVI's short term assets ($67.3M) exceed its long term liabilities ($816.0K).
Debt to Equity History and Analysis
Debt Level: TRVI is debt free.
Reducing Debt: TRVI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TRVI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TRVI has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 9.5% each year.